Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
NCT ID: NCT02348450
Last Updated: 2016-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
308 participants
INTERVENTIONAL
2015-02-28
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
NCT02171325
Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer
NCT02323737
A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer
NCT00349492
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
NCT00045162
Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
NCT02486354
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
An open-label, multi-center study will be conducted with dynamic randomization of approximately 1:1 ratio with an estimation of 308 eligible participants.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Irinotecan plus Cisplatin
first line: irinotecan 65mg/m2 d1,8. Cisplatin 30mg/m2，d1,8, 21days/cycle×6 cycles Second-line: etoposide alone OR etoposide plus cisplatin, dosage will be same as first line or on investigator's discretion.
Irinotecan
40mg
Cisplatin
6ml：30mg
Etoposide plus Cisplatin
first line: etoposide 60mg/m2 d1-5 Cisplatin 75mg/m2，d1(recommended), or administer three times with same total daily dose , 21days/cycle×6 cycles Second-line: irinotecan alone or irinotecan plus cisplatin, dosage is same as first line or on investigator's discretion.
Etoposide
5ml：0.1g
Cisplatin
6ml：30mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Irinotecan
40mg
Etoposide
5ml：0.1g
Cisplatin
6ml：30mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No prior radiotherapy, chemotherapy or surgery;
* At least one measurable lesion, CT≥20mm, spiral CT≥10mm(diameter);
* ECOG PS 0-1;
* Age 18-70;
* Life expectancy \> three months;
* In general normal function of heart, liver, kidney and bone marrow;
* WBC C\>4.0×10(9)/L, NEUT\>1.50×10(9)/L, PLT\>100×10(9)/L, Hb\>95g/L;
* Liver function: TBIL \< 1.5 x UL normal range; ALT and AST \< 1.5 x UL normal range;
* Kidney function: normal serum creatinine level;
* Signed an informed consent and will comply with the study protocol and follow-up plans.
Exclusion Criteria
* Have received prior chemotherapy or target treatment;
* Currently receiving other anticancer therapy;
* No measurable lesions or lesions cannot be assessed;
* Patients with acute or chronic medical or psychiatric condition, or laboratory abnormalities that may impact the judgment of the investigator and the result of the study, determined by investigator they may include:
Uncontrolled tumor metastasis in central nerve system; Uncontrolled hypertension, unstable angina, MI history, or congestive heart-failure, uncontrolled arrhythmia, ischemic vascular disease within the 12 months prior to study treatment; Myocardial ischemia by ECG or valvular heart disease; Grade 3 or above peripheral neuropathy; Active stage of infection by bacteria, fungi or virus; Pregnant or breast feeding woman; History of uncontrolled mental disease.
* Not able to discontinue NSAIDs treatment;
* Other active malignant tumors except non-melanoma skin cancer, in-situ cervical carcinoma and cured early prostatic carcinoma;
* Patients with allergies, known or may be allergic to drugs in research;
* Patients with poor compliance to treatment and follow-up;
* Patients with UGT1A1-6 and UGT1A1-28 gene mutation;
* With clinical symptoms of brain metastasis(patient with stable clinical performance and no need to treat can be included in the trial);
* Chest, abdominal or pericardial effusion that needs anti-cancer intervention;
* Accompanied with Grade ≥2 diarrhea;
* Participated in other clinical trials within one month before randomization;
* Investigator's judgment to exclude.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Association of Clinical Trials
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shun Lu, M.D
Role: PRINCIPAL_INVESTIGATOR
Shanghai Chest hospital of Shanghai Jiaotong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of AnHui Medical University
Hefei, Anhui, China
FuJian Provincial Tumor Hospital
Fuzhou, Fujian, China
Guangdong General Hospital
Guangzhou, Guangdong, China
Cancer Hospital Affiliated To GuangXi Medical University
Nanning, Guangxi, China
Fourth hospital of hebei medical university
Shijiazhuang, Hebei, China
The First Affiliated Hospital of HaErBin Medical University
Haerbin, Heilongjiang, China
HeNan Provincial Tumor Hospital
Zhengzhou, Henan, China
WuHan Tongji Hospital
Wuhan, Hubei, China
HuNan Provincial Tumor Hospital
Changsha, Hunan, China
JiangSu Provincial Tumor Hospital
Nanjing, Jiangsu, China
The First Affiliated Hospital of NanChang University
Nanchang, Jiangxi, China
LiaoNing Provincial Tumor Hospital
Shenyang, Liaoning, China
ShanDong Provincial Tumor Hospital
Jinan, Shandong, China
Linyi cancer hospital
Linyi, Shandong, China
Changhai Hospital of Shanghai
Shanghai, Shanghai Municipality, China
East Hospital Affiliated To Tongji University
Shanghai, Shanghai Municipality, China
Shanghai Chest hospital of Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
The second affiliated hospital of zhejiang university school of medicine
Hangzhou, Zhejiang, China
ZheJiang Provincial Tumor Hospital
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
gongyan chen
Role: primary
zhiyong Ma
Role: primary
yuan chen
Role: primary
jianhua chen
Role: primary
qisen guo
Role: primary
chong bai
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTONG1404
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.